|
1. Hayflick, L.; Moorhead, P. S., The serial cultivation of human diploid cell strains. Exp Cell Res 1961, 25, 585-621. 2. http://www.who.int/en/ 世界衛生組織網站. 3. http://www.doh.gov.tw/CHT2006/DM/DM2_2.aspx? now_fod_list_no=10238& class_no=440&level_no=1. 行政院衛生署網站. 4. Avendano, C. Medicinal Cmenistry of Anticancer Drugs; Elsevier: London, 2008. 5. Tan, C.; Tasaka, H.; Yu, K. P.; Murphy, M. L.; Karnofsky, D. A. Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia. Cancer 1967, 20, 333-353. 6. Coukell, A. J.; Faulds, D. Epirubicin. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of breast cancer. Drugs 1997, 53, 453-482. 7. (a) Kopka, M. L.; Yoon, C.; Goodsell, D.; Pjura, P.; Dickerson, R. E. The molecular origin of DNA-drug specificity in netropsin and distamycin. Proc. Natl. Acad. Sci. U. S. A. 1985, 82, 1376-1380; (b) Finlay, A. C.; Hochstein, F. A.; Sobin, B. A.; Murphy, F. X. Netropsin, a New Antibiotic Produced by a Streptomyces. Journal of the American Chemical Society 1951, 73, 341-343. 8. Kohler, G.; Milstein, C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975, 256, 495-497. 9. http://cdnet.stpi.org.tw/techroom/market/bio/bio031.htm. 單株抗體治療藥物. 10. Druker, B. J. Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML. Oncogene 2002, 21, 8541-8546. 11. Neidle, S. Cancer Drug Design and Discovery. Elsevier: London, 2008. 12. Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995, 1, 27-31. 13. http://www.tmn.idv.tw/tcfund/medecine/nm_42.htm. TNFerade 基因療法治療癌症之曙光. 14. http://www.medicalnewstoday.com/articles/129264.php. TNFerade□ Receives FDA Fast Track Designation For Treatment Of Pancreatic Cancer. 15. Normanno, N.; De Luca, A.; Bianco, C.; Strizzi, L.; Mancino, M.; Maiello, M. R.; Carotenuto, A.; De Feo, G.; Caponigro, F.; Salomon, D. S. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 2006, 366, 2-16. 16. Liu, Y.; Gray, N. S., Rational design of inhibitors that bind to inactive kinase conformations. Nat. Chem. Bio.l 2006, 2, 358-364. 17. Backes, A.; Zech, B.; Felber, B.; Klebl, B.; M□ller, G., Small-molecule inhibitors binding to protein kinases. Part I: exceptions from the traditional pharmacophore approach of type I inhibition. Expert Opinion on Drug Discovery 2008, 3, 1409-1425. 18. Backes, A.; Zech, B.; Felber, B.; Klebl, B.; M□ller, G. Small-molecule inhibitors binding to protein kinase. Part II: the novel pharmacophore approach of type II and type III inhibition. Expert Opin. Drug Discov. 2008, 3, 1427-1449. 19. Ghose, A. K.; Herbertz, T.; Pippin, D. A.; Salvino, J. M.; Mallamo, J. P. Knowledge based prediction of ligand binding modes and rational inhibitor design for kinase drug discovery. J. Med. Chem. 2008, 51, 5149-5171. 20. Li, R.; Stafford, J. A. Kinase Inhibitor Drugs; Wiley: New Jersey, 2009. 21. Wu, H. C.; Chang, D. K.; Huang, C. T., Targeted Therapy for Cancer. J. Cancer Mol. 2006, 2, 57-66. 22. Nyati, M. K.; Morgan, M. A.; Feng, F. Y.; Lawrence, T. S. Integration of EGFR inhibitors with radiochemotherapy. Nat. Rev. Cancer 2006, 6, 876-885. 23. Herbst, R. S.; Heymach, J. V.; Lippman, S. M. Lung cancer. N. Engl. J. Med. 2008, 359, 1367-1380. 24. Zhang, X.; Gureasko, J.; Shen, K.; Cole, P. A.; Kuriyan, J. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 2006, 125, 1137-1149. 25. Katarzyna, K. Adaptor Proteins in Regulation of Receptor Endocytosis. 2004. 26. Vivanco, I.; Sawyers, C. L. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat. Rev. Cancer 2002, 2, 489-501. 27. Bianco, R.; Gelardi, T.; Damiano, V.; Ciardiello, F.; Tortora, G. Rational bases for the development of EGFR inhibitors for cancer treatment. Int. J. Biochem. Cell Biol. 2007, 39, 1416-1431. 28. Katan, M. Families of phosphoinositide-specific phospholipase C: structure and function. Biochim. Biophys. Acta. 1998, 1436, 5-17. 29. Schlessinger, J. Cell signaling by receptor tyrosine kinases. Cell 2000, 103 211-225. 30. Aaronson, D. S.; Horvath, C. M. A Road Map for Those Who Don't Know JAK-STAT. Science 2002, 296, 1653-1655. 31. Salomon, D. S.; Brandt, R.; Ciardiello, F.; Normanno, N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol. 1995, 19, 183-232. 32. Sequist, L. V.; Bell, D. W.; Lynch, T. J.; Haber, D. A. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J. Clin. Oncol. 2007, 25, 587-595. 33. Huang, S. F.; Liu, H. P.; Li, L. H.; Ku, Y. C.; Fu, Y. N.; Tsai, H. Y.; Chen, Y. T.; Lin, Y. F.; Chang, W. C.; Kuo, H. P.; Wu, Y. C.; Chen, Y. R.; Tsai, S. F. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin. Cancer Res. 2004, 10, 8195-8203. 34. Sharma, S. V.; Bell, D. W.; Settleman, J.; Haber, D. A. Epidermal growth factor receptor mutations in lung cancer. Nat. Rev. Cancer 2007, 7, 169-181. 35. http://enews.nhri.org.tw/enews_list_new2.php?volume_indx=78&showx=show article&article_indx=2156&enews_dt=2004-12-21. 國家衛生研究院電子報 第78期:肺癌基因突變研究成果發表. 36. http://enews.nhri.org.tw/enews_list_new2.php?volume_indx=177&showx=show article&article_indx=4000&enews_dt=2006-11-22. 國家衛生研究院電子報第177期:肺癌基因突變和肺癌標靶治療藥物吉菲特尼(gefitinib)療效之新進展. 37. Kobayashi, S.; Boggon, T. J.; Dayaram, T.; Janne, P. A.; Kocher, O.; Meyerson, M.; Johnson, B. E.; Eck, M. J.; Tenen, D. G.; Halmos, B. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2005, 352, 786-792. 38. Pao, W.; Miller, V. A.; Politi, K. A.; Riely, G. J.; Somwar, R.; Zakowski, M. F.; Kris, M. G.; Varmus, H. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005, 2, 225-235. 39. Yun, C. H.; Mengwasser, K. E.; Toms, A. V.; Woo, M. S.; Greulich, H.; Wong, K. K.; Meyerson, M.; Eck, M. J. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc. Natl. Acad. Sci. U. S. A. 2008, 105, 2070-2075. 40. Fry, D. W.; Bridges, A. J.; Denny, W. A.; Doherty, A.; Greis, K. D.; Hicks, J. L.; Hook, K. E.; Keller, P. R.; Leopold, W. R.; Loo, J. A.; McNamara, D. J.; Nelson, J. M.; Sherwood, V.; Smaill, J. B.; Trumpp-Kallmeyer, S.; Dobrusin, E. M. Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor. Proc. Natl. Acad. Sci. U. S. A. 1998, 95, 12022-12027. 41. Cohen, M. S.; Zhang, C.; Shokat, K. M.; Taunton, J. Structural bioinformatics-based design of selective, irreversible kinase inhibitors. Science 2005, 308, 1318-1321. 42. Pan, Z.; Scheerens, H.; Li, S.-J.; Schultz, B. E.; Sprengeler, P. A.; Burrill, L. C.; Mendonca, R. V.; Sweeney, M. D.; Scott, K. C. K.; Grothaus, P. G.; Jeffery, D. A.; Spoerke, J. M.; Honigberg, L. A.; Young, P. R.; Dalrymple, S. A.; Palmer, J. T. Discovery of Selective Irreversible Inhibitors for Bruton’s Tyrosine Kinase. ChemMedChem 2007, 2, 58-61. 43. Adjei, A. A. Epidermal growth factor receptor tyrosine kinase inhibitors in cancer therapy. Drugs of the Future 2001, 26, 1087-1092. 44. Jiang, H. Overview of gefitinib in non-small cell lung cancer: an Asian perspective. Jpn. J. Clin. Oncol. 2009, 39, 137-150. 45. Norman, P. Kinase Therapeutics: Pipeline Assessment and Commercial Prospects Report. Insight Pharma Reports; Cambridge Healthech Institute (CHI): 2010. 46. Ng, S. S.; Tsao, M. S.; Nicklee, T.; Hedley, D. W. Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma. Mol. Cancer Ther. 2002, 1, 777-783. 47. Comis, R. L. The Current Situation: Erlotinib (Tarceva□) and Gefitinib (Iressa□) in Non-Small Cell Lung Cancer. Oncologist 2005, 10, 467-470. 48. Rigas, J. R. Erlotinib in non-small cell lung cancer. Community Oncol. 2005, 2, 205-209. 49. Spector, N. L.; Xia, W.; Burris, H., III; Hurwitz, H.; Dees, E. C.; Dowlati, A.; O'Neil, B.; Overmoyer, B.; Marcom, P. K.; Blackwell, K. L.; Smith, D. A.; Koch, K. M.; Stead, A.; Mangum, S.; Ellis, M. J.; Liu, L.; Man, A. K.; Bremer, T. M.; Harris, J.; Bacus, S. Study of the Biologic Effects of Lapatinib, a Reversible Inhibitor of ErbB1 and ErbB2 Tyrosine Kinases, on Tumor Growth and Survival Pathways in Patients With Advanced Malignancies. J. Clin. Oncol. 2005, 23, 2502-2512. 50. Morabito, A.; Piccirillo, M. C.; Falasconi, F.; De Feo, G.; Del Giudice, A.; Bryce, J.; Di Maio, M.; De Maio, E.; Normanno, N.; Perrone, F. Vandetanib (ZD6474), a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor (VEGFR) and Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinases: Current Status and Future Directions. Oncologist 2009, 14, 378-390. 51. Traxler, P.; Allegrini, P. R.; Brandt, R.; Brueggen, J.; Cozens, R.; Fabbro, D.; Grosios, K.; Lane, H. A.; McSheehy, P.; Mestan, J.; Meyer, T.; Tang, C.; Wartmann, M.; Wood, J.; Caravatti, G. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res. 2004, 64, 4931-4941. 52. Juengel, E.; Engler, J.; Natsheh, I.; Jones, J.; Mickuckyte, A.; Hudak, L.; Jonas, D.; Blaheta, R. A. Combining the receptor tyrosine kinase inhibitor AEE788 and the mammalian target of rapamycin (mTOR) inhibitor RAD001 strongly inhibits adhesion and growth of renal cell carcinoma cells. BMC Cancer 2009, 9, 161. 53. Gravalos, C.; Cassinello, J.; Fernandez-Ranada, I.; Holgado, E. Role of tyrosine kinase inhibitors in the treatment of advanced colorectal cancer. Clin. Colorectal Cancer 2007, 6, 691-699. 54. Wong, T. W. L., F. Y.; Feng, C. U.; Luo, R.; Oppenheimer, S.; Zhang, H. J.; Smykla, R. A.; Mastalerz, H.; Fink, B. E.; Hunt, J. T.; Gavai, A. V.; and Vite. G. D. Preclinical AntitumorActivity of BMS-599626 a pan-HER Kinase Inhibitor That Inhibits HER1HER2 Homodimer and Heterodimer Signaling. Clin. Cancer Res. 2006, 12, 6186-6193. 55. Gendreau, S. B.; Ventura, R.; Keast, P.; Laird, A. D.; Yakes, F. M.; Zhang, W.; Bentzien, F.; Cancilla, B.; Lutman, J.; Chu, F.; Jackman, L.; Shi, Y.; Yu, P.; Wang, J.; Aftab, D. T.; Jaeger, C. T.; Meyer, S. M.; De Costa, A.; Engell, K.; Chen, J.; Martini, J. F.; Joly, A. H. Inhibition of the T790M gatekeeper mutant of the epidermal growth factor receptor by EXEL-7647. Clin. Cancer Res. 2007, 13, 3713-3723. 56. Mukherji, D.; Spicer, J., Second-generation epidermal growth factor tyrosine kinase inhibitors in non-small cell lung cancer. Expert Opin. Investig. Drugs 2009, 18, 293-301. 57. Janne, P. A.; von Pawel, J.; Cohen, R. B.; Crino, L.; Butts, C. A.; Olson, S. S.; Eiseman, I. A.; Chiappori, A. A.; Yeap, B. Y.; Lenehan, P. F.; Dasse, K.; Sheeran, M.; Bonomi, P. D. Multicenter, Randomized, Phase II Trial of CI-1033, an Irreversible Pan-ERBB Inhibitor, for Previously Treated Advanced Non Small-Cell Lung Cancer. J. Clin. Oncol. 2007, 25, 3936-3944. 58. Nyati, M. K.; Maheshwari, D.; Hanasoge, S.; Sreekumar, A.; Rynkiewicz, S. D.; Chinnaiyan, A. M.; Leopold, W. R.; Ethier, S. P.; Lawrence, T. S. Radiosensitization by pan ErbB inhibitor CI-1033 in vitro and in vivo. Clin. Cancer Res. 2004, 10, 691-700. 59. Yoshimura, N.; Kudoh, S.; Kimura, T.; Mitsuoka, S.; Matsuura, K.; Hirata, K.; Matsui, K.; Negoro, S.; Nakagawa, K.; Fukuoka, M. EKB-569, a new irreversible epidermal growth factor receptor tyrosine kinase inhibitor, with clinical activity in patients with non-small cell lung cancer with acquired resistance to gefitinib. Lung Cancer 2006, 51, 363-368. 60. http://clinicaltrials.gov/ct2/home. 美國國家衛生院(NIH)網站. 61. Kwak, E. L.; Sordella, R.; Bell, D. W.; Godin-Heymann, N.; Okimoto, R. A.; Brannigan, B. W.; Harris, P. L.; Driscoll, D. R.; Fidias, P.; Lynch, T. J.; Rabindran, S. K.; McGinnis, J. P.; Wissner, A.; Sharma, S. V.; Isselbacher, K. J.; Settleman, J.; Haber, D. A. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc. Natl. Acad. Sci. U. S. A. 2005, 102, 7665-7670. 62. Rabindran, S. K.; Discafani, C. M.; Rosfjord, E. C.; Baxter, M.; Floyd, M. B.; Golas, J.; Hallett, W. A.; Johnson, B. D.; Nilakantan, R.; Overbeek, E.; Reich, M. F.; Shen, R.; Shi, X.; Tsou, H. R.; Wang, Y. F.; Wissner, A. Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res. 2004, 64, 3958-3965. 63. Li, D.; Shimamura, T.; Ji, H.; Chen, L.; Haringsma, H. J.; McNamara, K.; Liang, M. C.; Perera, S. A.; Zaghlul, S.; Borgman, C. L.; Kubo, S.; Takahashi, M.; Sun, Y.; Chirieac, L. R.; Padera, R. F.; Lindeman, N. I.; Janne, P. A.; Thomas, R. K.; Meyerson, M. L.; Eck, M. J.; Engelman, J. A.; Shapiro, G. I.; Wong, K. K. Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy. Cancer Cell 2007, 12, 81-93. 64. Discafani, C. M.; Carroll, M. L.; Floyd, M. B., Jr.; Hollander, I. J.; Husain, Z.; Johnson, B. D.; Kitchen, D.; May, M. K.; Malo, M. S.; Minnick, A. A., Jr.; Nilakantan, R.; Shen, R.; Wang, Y. F.; Wissner, A.; Greenberger, L. M. Irreversible inhibition of epidermal growth factor receptor tyrosine kinase with in vivo activity by N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide (CL-387,785). Biochem. Pharmacol. 1999, 57, 917-925. 65. Eskens, F. A.; Mom, C. H.; Planting, A. S.; Gietema, J. A.; Amelsberg, A.; Huisman, H.; van Doorn, L.; Burger, H.; Stopfer, P.; Verweij, J.; de Vries, E. G. A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours. Br. J. Cancer 2008, 98, 80-85. 66. Li, D.; Ambrogio, L.; Shimamura, T.; Kubo, S.; Takahashi, M.; Chirieac, L. R.; Padera, R. F.; Shapiro, G. I.; Baum, A.; Himmelsbach, F.; Rettig, W. J.; Meyerson, M.; Solca, F.; Greulich, H.; Wong, K. K. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 2008, 27, 4702-4711. 67. http://www.esmo.org/events/milan-2010-congress/news/view.html?tx_ttnews%5 Btt_news%5D=966&tx_ttnews%5BbackPid%5D=1798&cHash=ae58373bfc. Afatinib benefits lung cancer patients whose cancer progressed after treatment with EGFR inhibitors. 68. WHO, International Nonproprietary Names for Pharmaceutical Substances (INN). WHO Drug Information 2010, 24 (2), 125-198. 69. http://chembl.blogspot.com/ The CHEMBL-OG-Open Data For Drug Discovery. 70. http://chicago2010.asco.org/Home.aspx. The American Society of Clinical Oncology 2010 annual meeting. 71. Suzuki, T.; Fujii, A.; Ohya, J.; Amano, Y.; Kitano, Y.; Abe, D.; Nakamura, H. Pharmacological characterization of MP-412 (AV-412), a dual epidermal growth factor receptor and ErbB2 tyrosine kinase inhibitor. Cancer Sci. 2007, 98, 1977-1984. 72. Hickinson, D. M.; Klinowska, T.; Speake, G.; Vincent, J.; Trigwell, C.; Anderton, J.; Beck, S.; Marshall, G.; Davenport, S.; Callis, R.; Mills, E.; Grosios, K.; Smith, P.; Barlaam, B.; Wilkinson, R. W.; Ogilvie, D. AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer. Clin. Cancer Res. 2010, 16, 1159-1169. 73. Sequist, L. V. Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Oncologist 2007, 12, 325-330. 74. de La Motte Rouge, T.; Galluzzi, L.; Olaussen, K. A.; Zermati, Y.; Tasdemir, E.; Robert, T.; Ripoche, H.; Lazar, V.; Dessen, P.; Harper, F.; Pierron, G.; Pinna, G.; Araujo, N.; Harel-Belan, A.; Armand, J. P.; Wong, T. W.; Soria, J. C.; Kroemer, G. A novel epidermal growth factor receptor inhibitor promotes apoptosis in non-small cell lung cancer cells resistant to erlotinib. Cancer Res. 2007, 67, 6253-6262. 75. Wissner, A.; Overbeek, E.; Reich, M. F.; Floyd, M. B.; Johnson, B. D.; Mamuya, N.; Rosfjord, E. C.; Discafani, C.; Davis, R.; Shi, X.; Rabindran, S. K.; Gruber, B. C.; Ye, F.; Hallett, W. A.; Nilakantan, R.; Shen, R.; Wang, Y.-F.; Greenberger, L. M.; Tsou, H.-R. Synthesis and Structure−Activity Relationships of 6,7-Disubstituted 4-Anilinoquinoline-3-carbonitriles. The Design of an Orally Active, Irreversible Inhibitor of the Tyrosine Kinase Activity of the Epidermal Growth Factor Receptor (EGFR) and the Human Epidermal Growth Factor Receptor-2 (HER-2). J. Med. Chem. 2002, 46, 49-63. 76. Giaccone, G. Second-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. Advances in Lung Cancer 2007, 7, 9-13. 77. Wang, Y. N.; Ding, L. M.; Tan, F. L.; Hu, Y. Y.; He, W.; Han, B.; Long, W.; Liu, Y. Icotinib Hydrochlorides, Synthesis, Crystallographic Form, Medical Combination, and Uses Thereof. PCT Appl. CN2009/000773, Jan 14, 2010. 78. http://www.arraybiopharma.com/PatentsPublications/Default.asp?PBCategoryI D=3&Year=2010. 79. Lai, C. J.; Bao, R.; Tao, X.; Wang, J.; Atoyan, R.; Qu, H.; Wang, D. G.; Yin, L.; Samson, M.; Forrester, J.; Zifcak, B.; Xu, G. X.; DellaRocca, S.; Zhai, H. X.; Cai, X.; Munger, W. E.; Keegan, M.; Pepicelli, C. V.; Qian, C. CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity. Cancer Res. 2010, 70, 3647-3656. 80. Konings, I. R.; de Jonge, M. J.; Burger, H.; van der Gaast, A.; van Beijsterveldt, L. E.; Winkler, H.; Verweij, J.; Yuan, Z.; Hellemans, P.; Eskens, F. A. Phase I and pharmacological study of the broad-spectrum tyrosine kinase inhibitor JNJ-26483327 in patients with advanced solid tumours. Br. J. Cancer 2010, 103, 987-992. 81. Bruns, C. J.; Solorzano, C. C.; Harbison, M. T.; Ozawa, S.; Tsan, R.; Fan, D.; Abbruzzese, J.; Traxler, P.; Buchdunger, E.; Radinsky, R.; Fidler, I. J. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res. 2000, 60, 2926-2935. 82. Zhou, W.; Ercan, D.; Chen, L.; Yun, C. H.; Li, D.; Capelletti, M.; Cortot, A. B.; Chirieac, L.; Iacob, R. E.; Padera, R.; Engen, J. R.; Wong, K. K.; Eck, M. J.; Gray, N. S.; Janne, P. A. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 2009, 462, 1070-1074. 83. Lin, W. H.; Song, J. S.; Chang, T. Y.; Chang, C. Y.; Fu, Y. N.; Yeh, C. L.; Wu, S. H.; Huang, Y. W.; Fang, M. Y.; Lien, T. W.; Hsieh, H. P.; Chao, Y. S.; Huang, S. F.; Tsai, S. F.; Wang, L. M.; Hsu, J. T.; Chen, Y. R. A cell-based high-throughput screen for epidermal growth factor receptor pathway inhibitors. Anal. Biochem. 2008, 377, 89-94. 84. Gomi, K.; Kajiyama, N. Oxyluciferin, a Luminescence Product of Firefly Luciferase, Is Enzymatically Regenerated into Luciferin. J. Biol. Chem. 2001, 276, 36508-36513. 85. Gewald, K. Zur Reaktion von α-Oxo-mercaptanen mit Nitrilen. Angewandte Chemie 1961, 73 (3), 114-114. 86. Zita Puterova, A. K. a. D. V. Gewald reaction: synthesis, properties and applications of substituted 2-aminothiophenes. ARKIVOC 2010, 209-246. 87. Sabnis, R. W.; Rangnekar, D. W.; Sonawane, N. D. 2-aminothiophenes by the gewald reaction. J. Heterocyclic Chem. 1999, 36, 333-345. 88. Von Niementowski, S. Synthesen von Chinazolinverbindungen. Journal f□r Praktische Chemie 1895, 51, 564-572. 89. Hesse, S.; Perspicace, E.; Kirsch, G. Microwave-assisted synthesis of 2-aminothiophene-3-carboxylic acid derivatives, 3H-thieno[2,3-d]pyrimidin-4- one and 4-chlorothieno[2,3-d]pyrimidine. Tetrahedron Lett. 2007, 48, 5261-5264. 90. SALAHUDDIN, M.; KAKAD, S.; SHANTAKUMAR, S. M. Synthesis of Some Novel Thieno[2, 3-d] pyrimidines and their Antibacterial Activity. E. J. Chem. 2009, 6, 801-808. 91. Barnes, D. M.; Haight, A. R.; Hameury, T.; McLaughlin, M. A.; Mei, J.; Tedrow, J. S.; Riva Toma, J. D. New conditions for the synthesis of thiophenes via the Knoevenagel/Gewald reaction sequence. Application to the synthesis of a multitargeted kinase inhibitor. Tetrahedron 2006, 62, 11311-11319. 92. Hwang, K.-J.; Lee, T.-S.; Kim, K.-W.; Kim, B.-T.; Lee, C.-M.; Park, E.-Y.; Woo, R.-S. 4-Hydroxy-6-Oxo-6,7-Dihydro-Thieno[2,3-b] pyrimidine derivatives: Synthesis and their biological evaluation for the glycine site acting on the N-Methyl-D-aspartate (NMDA) receptor. Arch. Pharm. Res. 2001, 24, 270-275. 93. Huang, Y.; Domling, A. The Gewald multicomponent reaction. Mol. Divers. 2010, 1-31. 94. M□ller, C. E.; Geis, U.; Grahner, B.; Lanzner, W.; Eger, K. Chiral pyrrolo[2,3-d]pyrimidine and pyrimido[4,5-b]indole derivatives: structure-activity relationships of potent, highly stereoselective A1-adenosine receptor antagonists. J. Med. Chem. 1996, 39, 2482-2491. 95. DiMauro, E. F.; Newcomb, J.; Nunes, J. J.; Bemis, J. E.; Boucher, C.; Buchanan, J. L.; Buckner, W. H.; Cheng, A.; Faust, T.; Hsieh, F.; Huang, X.; Lee, J. H.; Marshall, T. L.; Martin, M. W.; McGowan, D. C.; Schneider, S.; Turci, S. M.; White, R. D.; Zhu, X. Discovery of 4-amino-5,6-biaryl-furo[2,3-d]pyrimidines as inhibitors of Lck: Development of an expedient and divergent synthetic route and preliminary SAR. Bioorg. Med. Chem. Lett. 2007, 17, 2305-2309. 96. Selles Patrice; Wailes Jeffrey Steven; Whittingham William Guy; Daniel, C. E. FUNGICIDES. PCT Appl. GB2004/004429, May 19, 2005. 97. Lima, L. M.; Barreiro, E. J. Bioisosterism: a useful strategy for molecular modification and drug design. Curr. Med. Chem. 2005, 12, 23-49. 98. Hagmann, W. K. The many roles for fluorine in medicinal chemistry. J. Med. Chem. 2008, 51, 4359-4369. 99. Coumar, M. S.; Chu, C. Y.; Lin, C. W.; Shiao, H. Y.; Ho, Y. L.; Reddy, R.; Lin, W. H.; Chen, C. H.; Peng, Y. H.; Leou, J. S.; Lien, T. W.; Huang, C. T.; Fang, M. Y.; Wu, S. H.; Wu, J. S.; Chittimalla, S. K.; Song, J. S.; Hsu, J. T.; Wu, S. Y.; Liao, C. C.; Chao, Y. S.; Hsieh, H. P. Fast-forwarding hit to lead: aurora and epidermal growth factor receptor kinase inhibitor lead identification. J. Med. Chem. 2010, 53, 4980-4998. 100. Wissner, A.; Mansour, T. S. The development of HKI-272 and related compounds for the treatment of cancer. Arch. Pharm. 2008, 341, 465-477. 101. Traxler, P.; Allegrini P. R.; Brandt, R.; Brueggen, J.; Cozens, R.; Fabbro, D.; Grosios, K.; Lane, H. A.; McSheehy, P.; Mestan, J.; Meyer, T.; Tang, C.; Wartmann, M.; Wood, J.; Caravatti, G. AEE788: A Dual Family Epidermal Growth Factor Receptor/ErbB2 and Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor with Antitumor and Antiangiogenic Activity. Cancer Res. 2004, 64, 4931–4941. 102. Bridges, A. J.; Cody, D. R.; Zhou, H.; McMichael, A.; Fry, D. W. Enantioselective inhibition of the epidermal growth factor receptor tyrosine kinase by 4-(alpha-phenethylamino)quinazolines. Bioorg. Med. Chem. 1995, 3, 1651-1656. 103. Hagmann, W. K. The many roles for fluorine in medicinal chemistry. J. Med. Chem. 2008, 51, 4359-4369. 104. Armarego, W. L. F.; Chai, C. Purification of Laboratory Chemicals; 4th. Ed. Pergamon Press: New York, 1996.
|